Pipeline
Boldly differentiated medicines
We are translating evolutionary insights into a pipeline of first-in-class programs, intercepting the fundamental drivers of cardiometabolic and immunological diseases before they lead to chronic dysfunction.
Our pipeline
Target ID/
Validation
Preclinical
Clinical
IMMUNOLOGY AND INFLAMMATION (I&I)
Inflammasome (ASC)
Target ID/
Validation
Lead ID &
Optimization
Preclinical
Clinical
Multiple targets
Target ID/
Validation
Lead ID &
Optimization
Preclinical
Clinical
CARDIOMETABOLISM
Target A
Target ID/
Validation
Lead ID &
Optimization
Preclinical
Clinical
Multiple targets
Target ID/
Validation
Lead ID &
Optimization
Preclinical
Clinical
PS-1001: a first-in-class pan-inflammasome inhibitor
PS-1001 is our lead therapeutic candidate, being developed as a potential first-in-class therapy for diseases driven by excessive inflammasome activation.
PS-1001 is designed to neutralize ASC, a master scaffold of the inflammasome complex. While traditional approaches often target downstream cytokines, PS-1001 interrupts the inflammatory cascade at its source.
Developed through our collaboration with the Duke-NUS Medical School, PS-1001 is inspired by evolutionary adaptations that suppress excessive inflammasome activation. PS-1001 features a dual-action mechanism: It prevents the assembly of new inflammasome complexes within the cell and actively disassembles existing extracellular complexes to quench ongoing inflammation.
Therapeutic focus areas
Immunological & inflammatory diseases
Current treatments often struggle to balance efficacy with safety, frequently leading to broad immunosuppression. Paratus is changing this paradigm by decoding species that mount effective antiviral defenses while maintaining precise inflammatory control.
By targeting these evolutionarily validated pathways, we aim to restore immune homeostasis and stop disease progression without compromising the body’s natural defenses.
Cardiometabolic diseases
Cardiometabolic dysfunction is often driven by a failure of energy homeostasis and cellular stress management. We look to biological outliers that maintain peak metabolic performance under extreme physiological demands.
These naturally occurring adaptations provide a roadmap for new therapies that regulate metabolism and cardiovascular function, addressing the underlying drivers of cardiometabolic disease.
Our discovery engine
Our pipeline begins with insights from evolutionary biology and resilient biological traits. Learn how Paratus’s discovery platform identifies new therapeutic opportunities.